SEATTLE — In this video, Rishi P. Singh, MD, FASRS, discusses presentations on faricimab from the ASRS annual meeting.
Faricimab is the first bispecific antibody for retinal diseases, Singh, president of Martin North and South Hospitals and professor of ophthalmology at Cleveland Clinic Lerner College of Medicine, said.
“[The meeting] had a variety of interesting outcomes and presentations that were given,” Singh said, including the finding that faricimab had a lower rate of epiretinal membrane growth.
“This again shows us that there is significant benefit in faricimab in